Pfizer's Draxxin hits the market
New York — Pfizer introduces Draxxin, an antibacterial treatment for bovine respiratory disease (BRD) and swine respiratory disease (SRD).
NEW YORK — Pfizer introduces Draxxin, an antibacterial treatment for bovine respiratory disease (BRD) and swine respiratory disease (SRD).
The company says the drug sets a new standard of effectiveness for treatment of costly livestock diseases.
Draxxin delivers a full course of therapy in a single dose, the company adds. Field trials demonstrate that one dose of the product provides efficacy in treating BRD and SRD.
Draxxin may be used as a preventative method and is the first animal antimicrobial to receive approval following the U.S. Food and Drug Administration's new Guidance 152 review process that included a public review by the Food and Drug Administration Veterinary Medical Advisory Committee of safety with respect to the potential for transfer of antimicrobial resistance to humans.
Draxxin moves easily through syringes, even in cold conditions, the company says.
The product is sold ready-to-use in 100mL, 250mL and 500mL vials.
Draxxin is administered subcutaneously in cattle and is an intramuscular administration in swine.
Draxxin may be stored at room temperature for 36 months, the company adds.
For fastest response, call
(888) 372-9946
